Koen Van Besien to Follow-Up Studies
This is a "connection" page, showing publications Koen Van Besien has written about Follow-Up Studies.
Connection Strength
0.473
-
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019 07; 60(7):1693-1696.
Score: 0.097
-
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303.
Score: 0.079
-
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63.
Score: 0.049
-
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8.
Score: 0.030
-
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404.
Score: 0.028
-
Allogeneic transplantation for low-grade lymphoma: long-term follow-up. J Clin Oncol. 2000 Feb; 18(3):702-3.
Score: 0.026
-
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
Score: 0.022
-
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102.
Score: 0.019
-
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995 Apr; 15(4):549-55.
Score: 0.019
-
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1040-5.
Score: 0.016
-
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
Score: 0.015
-
Pregnancy-associated aplastic anemia--report of 3 cases. Eur J Haematol. 1991 Oct; 47(4):253-6.
Score: 0.015
-
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Jan; 17(1):124-32.
Score: 0.013
-
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan; 16(1):35-45.
Score: 0.013
-
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
Score: 0.009
-
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.
Score: 0.008
-
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15; 98(6):1695-700.
Score: 0.007
-
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb; 27(4):387-96.
Score: 0.007
-
Endoscopic sclerotherapy of esophageal varices. Long-term follow-up, recurrence, and survival. J Clin Gastroenterol. 1988 Aug; 10(4):368-72.
Score: 0.003